The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

Studies designed, executed, and funded by an Alkermes company.

Filter Publications
Therapeutic Area:
Publication Type:
Showing 10 of 103 results
Sort by date: Descending
Mar 2021
Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia
BMC Psychiatry
AUTHOR(S)
McEvoy JP, Weiden PJ, Lysaker PH, Sun X, O'Sullivan AK
View on PubMed
Clinical
Schizophrenia
Dec 2020
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial
Addictive Behaviors
AUTHOR(S)
Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA
View on PubMed
Clinical
Opioid Use Disorder
Dec 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
The American Journal of Psychiatry
AUTHOR(S)

Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, Du Y, Simmons A, Hopkinson C, McDonnell D, Kahn RS

View on PubMed
Clinical
Schizophrenia
Sep 2020
Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey
Patient Preference and Adherence
AUTHOR(S)

Doane MJ, Sajatovic M, Weiden PJ, O'Sullivan AK, Maher S, Bjorner JB, Sikora Kessler A, Carpenter-Conlin J, Bessonova L, Velligan DI

View on PubMed
Real World Evidence
Schizophrenia
Aug 2020
Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study
CNS Drugs
AUTHOR(S)
Weiden PJ, Du Y, von Moltke L, Wehr A, Hard M, Marandi M, Walling DP
View on PubMed
Clinical
Schizophrenia
Jul 2020
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study
The Journal of Clinical Psychiatry
AUTHOR(S)
Lauriello J, Claxton A, Du Y, Weiden PJ
View on PubMed
Clinical
Schizophrenia
Jun 2020
Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey
BMC Psychiatry
AUTHOR(S)

Bessonova L, Velligan DI, Weiden PJ, O'Sullivan AK, Yarlas A, Bayliss M, Baranwal N, Rychlec K, Carpenter-Conlin J, Doane MJ, Sajatovic M

View on PubMed
Real World Evidence
Bipolar Disorder
Jun 2020
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
The American Journal on Addictions
AUTHOR(S)
Comer SD, Mannelli P, Alam D, Douaihy A, Nangia N, Akerman SC, Zavod A, Silverman BL, Sullivan MA
View on PubMed
Clinical
Opioid Use Disorder
May 2020
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT/QTc study
Progress in Neuro-Psychopharmacology & Biological Psychiatry
AUTHOR(S)

Sun L, Yagoda S, Xue H, Brown R, Nangia N, McDonnell D, Rege B, von Moltke L, Darpo B

View on PubMed
Clinical
Bipolar Disorder
Schizophrenia
May 2020
Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia
CNS Spectrums
AUTHOR(S)

Jain R, Meyer J, Wehr A, Rege B, von Moltke L, Weiden PJ

View on PubMed
Review/Commentary
Schizophrenia